Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy

• Status: Not yet recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the possible efficacy of Carvedilol as gastroprotective agent against aspirin-induced upper gastro-intestinal complications in patients with ischemic heart disease (IHD).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

1. Age 25-60 years.

2. Both genders.

3. Patient with IHD including myocardial infarction, unstable angina and chronic stable angina on aspirin therapy.

4. Patients with hypertension.

5. Patients on low dose aspirin therapy for at least 3 months.

Exclusion Criteria:

1. Subjects with history of gastrointestinal disease, gastroduodenal surgery, H. pylori infection.

2. History or current diagnosis of major depressive disorder or other psychiatric disorders.

3. Patients already under histamine-2 receptor antagonist, proton pump inhibitor, misoprostol or gastrofate within 2 weeks of entering this study.

4. Patients who are allergic to aspirin and NSAIDs, who have an intolerance to aspirin and NSAIDs.

5. Subjects with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders.

6. Pregnancy or lactation.

7. Patients with severe hepatic impairment (Child-Pugh class B and C) or total bilirubin level ≥ 1.2 mg/dl.

8. Patients with renal impairment (creatinine clearance less than 50mg/dl).